Cancer surgeon-scientist @PennMedicine. Our lab advances therapy for #headandneckcancer #HPV #hnscm. Opinions my own. Patient appointments 2156626972
Philadelphia
Joined May 2019
- Tweets478
- Following1.6K
- Followers838
- Likes2K
Well written review by @imrtlee @xrtGenomics et al and an easy read for the non-rad onc, contextualizing differences between the two phase III trials comparing IMRT to IMPT for oropharyngeal cancer. ascopubs.org/doi/full/10.120…
Devraj Basu, MD, PhD, FACS retweeted
genuinely bullish on this #papertrade
Devraj Basu, MD, PhD, FACS retweeted
decidedly set up well #papertrade
Devraj Basu, MD, PhD, FACS retweeted
🦠💡Next up - TRINITY trial presented by Zachary Zumsteg at @CedarsSinai, investigating reduced dose/volume CRT after TORS with excellent 2-yr PFS.
#ASTRO26 @ASTRO_org
@xrtGenomics @DanielMaMD @RobertFerrisMD @drdavidpalma
Devraj Basu, MD, PhD, FACS retweeted
So proud to be a Pennsylvanian with a Republican Senator like Dave McCormick. Thank you Senator McCormick for strongly supporting biomedical research and NIH.
washingtonpost.com/opinions/…
I think reliable, but for a different disease - I don't claim much expertise given rarity of EBV+ NPC in the US.
I agree we are headed that way - HPV ctDNA seems quite specific in most clinical contexts. There are sensitivity issues (as there are with RNAScope), and the nature of those false negatives may be contingent on ctDNA assay used.
Highlighting our infographic with @AHNS on the significance of discordant HPV confirmatory testing in p16+ oropharyngeal cancer and current US guidelines for using it.
Presented by the AHNS Annual Basic & Translational Science Service. Prepared by @MollyEHeftNeal and @basulab1, this infographic explores HPV/p16 discordance in oropharyngeal cancer, its prognostic & therapeutic relevance, and implications for confirmatory HPV testing.
#AHNS
Devraj Basu, MD, PhD, FACS retweeted
Very thoughtful commentary from the stellar Red Journal H&N editors!
redjournal.org/article/S0360…
Devraj Basu, MD, PhD, FACS retweeted
Question born in a clinic. 74 patients with HNSCC undergoing CTRT. Two blinded oncologists grading toxicities.
Now in Red Journal
Mucositis, ≥G2 κ: 0.23–0.41 | 91.9% vs 70.2%,
Assessor = hidden covariate in every tox endpoint
doi.org/rmn6
@IJROBP @RadOncTMC
Devraj Basu, MD, PhD, FACS retweeted
The final paper from Gough/Crittenden Lab @providence is out in J of Immunology.
Kaede tracking shows the tumor-draining lymph node refills irradiated tumors with T cells — support for lymphatic-sparing immunoradiotherapy in H&N cancer. academic.oup.com/jimmunol/ar…
Devraj Basu, MD, PhD, FACS retweeted
Updated results from JCOG 1008 (bolus versus weekly cis for postoperative CRT in high-risk patients) are out.
Weekly cisplatin was clearly non-inferior and in fact numerically superior from both a disease- and safety- perspective. The clear winner.
It will be very interesting to see the final results from HN009 (definitive CRT), especially in an HPV-negative population that may be at higher risk for treatment-related toxicity.
ascopubs.org/doi/full/10.120…
Devraj Basu, MD, PhD, FACS retweeted
Mark was a phenomenal human being and leader - a great loss.
Mark A. Varvares, MD, FACS, passed away on May 20, 2026 surrounded by his family leaving behind a legacy defined by the countless lives he has touched
Viewing and funeral service will be Saturday, May 30th, St Nicholas Greek Orthodox Church in St Louis, MO
buff.ly/iORf2w8
Some interesting results to unpack here
Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc @DanaFarberNews @jdschoenfeld1
nature.com/articles/s41467-0…
